Related references
Note: Only part of the references are listed.Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)
Peter Horak et al.
GENETICS IN MEDICINE (2022)
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions
Diana Bradford et al.
CLINICAL CANCER RESEARCH (2021)
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions
Janice Kim et al.
CLINICAL CANCER RESEARCH (2021)
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Vivek Subbiah et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Neoadjuvant selpercatinib for advanced medullary thyroid cancer
Yelda Jozaghi et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2021)
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
L. J. Wirth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing
Raffaele Ciampi et al.
ISCIENCE (2019)
Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience
Shuanzeng Wei et al.
ENDOCRINE PATHOLOGY (2016)
New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations
Cristina Romei et al.
JOURNAL OF MEDICAL GENETICS (2016)
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma
Cristina Romei et al.
NATURE REVIEWS ENDOCRINOLOGY (2016)
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma
Andreas M. Heilmann et al.
ONCOLOGY (2016)
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
Samuel A. Wells et al.
THYROID (2015)
Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer
Jun Ho Ji et al.
PLOS GENETICS (2015)
High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas
Michele Simbolo et al.
VIRCHOWS ARCHIV (2014)
Exomic Sequencing of Medullary Thyroid Cancer Reveals Dominant and Mutually Exclusive Oncogenic Mutations in RET and RAS
Nishant Agrawal et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Structure and Physiology of the RET Receptor Tyrosine Kinase
Carlos F. Ibanez
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
Razelle Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Important role of indels in somatic mutations of human cancer genes
Haiwang Yang et al.
BMC MEDICAL GENETICS (2010)
Small insertions and deletions (INDELs) in human genomes
Julienne M. Mullaney et al.
HUMAN MOLECULAR GENETICS (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Human gene mutation database (HGMD®):: 2003 update
PD Stenson et al.
HUMAN MUTATION (2003)
The finding of a somatic deletion in RET exon 15 clarified the sporadic nature of a medullary thyroid carcinoma suspected to be familial
J Oriola et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2002)
A novel type of mutation in the cysteine rich domain of the RET receptor causes ligand independent activation
DH Arlt et al.
ONCOGENE (2000)
Share Paper
